Imaging agent developer ImaginAb is touting results from a clinical trial of IAB2M, the company's PET imaging agent for the detection of metastatic prostate cancer.
Researchers at Memorial Sloan Kettering Cancer Center found that the radiolabeled monoclonal antibody, designed to target prostate-specific membrane antigen (PSMA), detected bone lesions and soft-tissue lesions with greater specificity and sensitivity than standard imaging methods.
The phase I/IIA study included 38 patients with progressive metastatic prostate cancer who underwent standard imaging using CT, bone scintigraphy, and FDG-PET, followed by imaging with IAB2M.
IAB2M detected 344 bone lesions (84%), compared with 209 lesions (51%) by CT, 211 lesions (51%) through bone scintigraphy, and 109 lesions (27%) with FDG-PET. For soft tissue, IAB2M detected 119 lesions (81%), compared with 83 lesions (57%) using CT and 79 lesions (54%) with FDG-PET.
The study is scheduled for presentation on January 7 at the 2016 Genitourinary Cancers Symposium in San Francisco.
